Stories of progress, inspiration, and information in overcoming osteosarcoma.

Breaking New Ground: The OSI’s 2024 Research Grant Recipients

Optimism surrounds osteosarcoma research as the OSI awards $1.1 million in cancer research funding to three innovative projects.

This year, the Osteosarcoma Institute (OSI) awarded $1.1 million in osteosarcoma research funding to three groundbreaking projects during its 2023–2024 grant cycle. After an extensive review process, the OSI’s committee of experts selected two translational studies and one high-risk/high-impact study.

Understanding Translational vs. High-Risk/High-Impact Cancer Research

Beginning in 2019, the OSI began awarding cancer research grants in three categories: translational research, clinical trials, and correlative science.

This year, under the guidance of Lee Helman, MD, an osteosarcoma expert who has been studying the biology and caring for pediatric patients with sarcomas for over thirty years, the OSI added a new, fourth category: high-risk/high-impact research.

Lee Helman, MD, Institute Director

“Current therapy for patients with osteosarcoma has not improved over the past 40 years. I believe that with our improved understanding of the genetic drivers of this disease, we have an unprecedented opportunity to make significant progress in treating patients using this information,” Dr. Helman says. “I also believe we have the opportunity to engage the immune system to help us develop new approaches for treatment. And I believe the OSI can help accelerate our progress in making this a reality.”

[et_pb_acf_single_item field_name=”Posts|image_gallery” image_size=”et-pb-image–responsive–phone” admin_label=”First Gallery” module_class=”first-gallery” _builder_version=”4.17.4″ _module_preset=”default” display_conditions=”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” global_colors_info=”{}”][/et_pb_acf_single_item][et_pb_acf_single_item field_name=”Posts|gallery_texts” image_size=”et-pb-image–responsive–phone” admin_label=”First Gallery” module_class=”first-gallery” _builder_version=”4.17.4″ _module_preset=”default” text_font=”Open Sans|600|on||||||” text_text_color=”#000000″ text_font_size=”13px” display_conditions=”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” global_colors_info=”{}”][/et_pb_acf_single_item][et_pb_acf_single_item field_name=”Posts|2nd_content” _builder_version=”4.18.0″ _module_preset=”default” text_text_color=”#000000″ text_line_height=”25px” headings_font=”Brandon Grotesque Bold||||||||” headings_font_size=”26px” display_conditions=”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” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][/et_pb_acf_single_item]

[et_pb_acf_single_item field_name=”Posts|3rd_content” _builder_version=”4.27.4″ _module_preset=”default” text_text_color=”#000000″ headings_font=”Brandon Grotesque Bold||||||||” headings_font_size=”26px” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][/et_pb_acf_single_item]

“The outcome we are looking for is to have more patients survive osteosarcoma,” Dr. Helman says. “I think each of these grants has a very good chance of getting answers to some important questions that we can then build on to make that happen.”

[et_pb_acf_single_item field_name=”Posts|4th_content” _builder_version=”4.18.0″ _module_preset=”default” text_text_color=”#000000″ headings_font=”Brandon Grotesque Bold||||||||” headings_font_size=”26px” display_conditions=”W10=” global_colors_info=”{}”][/et_pb_acf_single_item]

[et_pb_acf_single_item field_name=”Posts|5th_content” _builder_version=”4.18.0″ _module_preset=”default” text_text_color=”#000000″ headings_font=”Brandon Grotesque Bold||||||||” headings_text_color=”#000000″ headings_font_size=”26px” display_conditions=”W10=” global_colors_info=”{}”][/et_pb_acf_single_item]